High-resolution 3D visualization of nanomedicine distribution in tumors.
Animals
Cell Line, Tumor
Contrast Media
/ chemistry
Humans
Imaging, Three-Dimensional
/ methods
Liposomes
/ chemistry
Male
Mice
Mice, SCID
Nanomedicine
/ methods
Nanoparticles
/ administration & dosage
Neoplasms
/ diagnostic imaging
Permeability
Tumor Microenvironment
X-Ray Microtomography
/ methods
Xenograft Model Antitumor Assays
EPR
distribution
nanomedicine
tumor microenvironment
vasculature.
µCT imaging
Journal
Theranostics
ISSN: 1838-7640
Titre abrégé: Theranostics
Pays: Australia
ID NLM: 101552395
Informations de publication
Date de publication:
2020
2020
Historique:
received:
31
05
2019
accepted:
16
10
2019
entrez:
7
1
2020
pubmed:
7
1
2020
medline:
22
4
2021
Statut:
epublish
Résumé
To improve the clinical translation of anti-cancer nanomedicines, it is necessary to begin building specific insights into the broad concept of the Enhanced Permeability and Retention (EPR) effect, using detailed investigations of the accumulation, distribution and retention of nanomedicines in solid tumors. Nanomedicine accumulation in preclinical tumors has been extensively studied; however, treatment efficacy will be heavily influenced by both the quantity of drug-loaded nanomedicines reaching the tumor as well as their spatial distribution throughout the tumor. It remains a challenge to image the heterogeneity of nanomedicine distribution in 3 dimensions within solid tumors with a high degree of spatial resolution using standard imaging approaches.
Identifiants
pubmed: 31903157
doi: 10.7150/thno.37178
pii: thnov10p0880
pmc: PMC6929971
doi:
Substances chimiques
Contrast Media
0
Liposomes
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
880-897Informations de copyright
© The author(s).
Déclaration de conflit d'intérêts
Competing interests: JIM, HB, S-AE, NS, JM, RJAG, SP, MBA, STB are present or past employees and shareholders of AstraZeneca PLC.
Références
Clin Cancer Res. 2001 Feb;7(2):243-54
pubmed: 11234875
Cancer Res. 2013 Apr 15;73(8):2412-7
pubmed: 23423979
Adv Drug Deliv Rev. 2013 Jan;65(1):80-8
pubmed: 23036224
ACS Nano. 2013 Sep 24;7(9):7442-7
pubmed: 24490875
Adv Drug Deliv Rev. 2017 Jan 1;108:25-38
pubmed: 27137110
Theranostics. 2017 Jan 1;7(2):253-269
pubmed: 28042332
Theranostics. 2016 Sep 9;6(12):2039-2051
pubmed: 27698939
Theranostics. 2016 May 21;6(8):1131-44
pubmed: 27279907
J Control Release. 2014 May 28;182:83-9
pubmed: 24631862
Nanomedicine. 2015 Jul;11(5):1247-52
pubmed: 25752857
Cancer. 1994 Mar 1;73(5):1478-84
pubmed: 8111716
Theranostics. 2017 Jan 7;7(3):538-558
pubmed: 28255348
Am J Pathol. 2014 Feb;184(2):431-41
pubmed: 24262753
J Control Release. 2013 Nov 28;172(1):351-357
pubmed: 24021358
Nano Lett. 2019 Feb 13;19(2):997-1008
pubmed: 30676760
Nat Biomed Eng. 2018 Nov;2(11):797-809
pubmed: 30931172
Proc Natl Acad Sci U S A. 1988 Sep;85(18):6949-53
pubmed: 3413128
Pharm Res. 2007 Jun;24(6):1193-201
pubmed: 17373581
Mol Pharm. 2009 Mar-Apr;6(2):571-80
pubmed: 19298061
Nat Rev Cancer. 2017 Jan;17(1):20-37
pubmed: 27834398
Nat Commun. 2013;4:2516
pubmed: 24084631
J Control Release. 2015 Jun 10;207:101-11
pubmed: 25862513
Nat Nanotechnol. 2012 Apr 08;7(6):383-8
pubmed: 22484912
Adv Drug Deliv Rev. 2018 May;130:17-38
pubmed: 30009886
J Proteomics. 2012 Aug 30;75(16):5106-5110
pubmed: 22842151
Theranostics. 2019 Mar 16;9(7):1893-1908
pubmed: 31037146
Sci Transl Med. 2016 Feb 10;8(325):325ra17
pubmed: 26865565
Drugs. 1997;54 Suppl 4:8-14
pubmed: 9361956
Chem Rev. 2015 Oct 14;115(19):10907-37
pubmed: 26166537
Invest Radiol. 2006 Mar;41(3):339-48
pubmed: 16481918
J Control Release. 2015 Aug 10;211:163-70
pubmed: 26070245
Mol Imaging Biol. 2018 Oct;20(5):683-695
pubmed: 30084044
Cancer Res. 1994 Feb 15;54(4):987-92
pubmed: 8313389
J Control Release. 2015 Dec 10;219:192-204
pubmed: 26277065
J Am Soc Mass Spectrom. 2013 May;24(5):718-21
pubmed: 23536269
Clin Transl Med. 2018 Mar 1;7(1):11
pubmed: 29541939